tbuckley/cabot-search huggingface dataset:
When does a breast milk substitute become an essential medicine?
Authors: R M Beattie, A Batra, L V Marino, M J Johnson
Journal: BMJ (2019)

BMJ recently made the decision to stop publishing adverts from formula milk companies. 1This is an appropriate strategy to help with national and international initiatives to promote breastfeeding, but it has potentially complex and far reaching ramifications.This includes a potential vulnerability for the small group of infants for whom breastfeeding is not possible or appropriate because of underlying medical conditions.
PANEL DISCUSSION ON PEPTIC ULCER
Authors: C J BARBORKA, E C TEXTER, R B LEWIS, W W CARROLL, R J BOLT
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Achromotrichia in Tropical Malnutrition
Authors: S. K. Roy
Journal: BMJ (1947)

BKIlOStL too all the signs of meningism, including nuchal rigidity and Kernig's sign.Blood films on admission were negative for malarial parasites, but despite this and during preparations for withdrawal of C.S.F. it was suggested that he be given intravenous quinine, 10 gr. (0.65 g.).Half an hour after administration delirium had ceased, and lying comfortably in bed he spoke quietly and coherently and was curious to know what had happened to him.Examination of the C.S.F. was then carried out and meningitis excluded as a concomitant condition.Malaria is a great simulator, and while not having had the opportunity of reading Dr. Walter Broadbent's letter (Jan. 4,p. 32) I conclude this fact was uppermost in his mind when approaching his case.-Iam, etc.,
Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma
Authors: Jithma P. Abeykoon, David L Murray, Isaiah Murray, Dragan Jevremovic, Angela Dispenzieri, Bonnie Kaye Arendt, Surendra Dasari, Morie A Gertz, Wilson I Gonsalves, Taxiarchis Kourelis, Eli Muchtar, David Dingli, Rahma M Warsame, Ronald S. Go, Martha Q. Lacy, Nelson Leung, Francis K. Buadi, Yi Lin, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar, Prashant Kapoor
Journal: Blood (2019)
Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Authors: Mary-Elizabeth M. Percival, Megan Othus, Sarah Mirahsani, Kelda M. Gardner, Carole M. Shaw, Anna B. Halpern, Paul C. Hendrie, Pamela S. Becker, Mohamed L. Sorror, Roland B. Walter, Elihu H. Estey
Journal: Blood (2019)
Primary Leiomyosarcoma of the Bronchus
Authors: Chongjiao Li, Yueli Tian, Ying Shen, Bing Wen, Yong He
Journal: Clinical Nuclear Medicine (2019)

Primary leiomyosarcoma of the bronchus is an extremely rare malignant neoplasm. A 29-year-old man presented with persisting cough and sputum over 1 month. Unenhanced and contrast-enhanced chest CT showed a nodular lesion in the main bronchus of the left lower lobe and multiple enlarged lymph nodes in the mediastinum. Preoperative staging F-FDG PET/CT scan displayed a hypermetabolic lesion of the known nodule and mild FDG uptake of mediastinal lymph nodes. The histological examination confirmed bronchial leiomyosarcoma and reactive hyperplasia in lymph nodes.
PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
Authors: T. Leal, H. Wakelee, K.L. Reckamp, A. Chiappori, G.R. Oxnard, S.N. Waqar, S.P. Patel, G.R. Blumenschein, J.W. Neal, K. Harrow, A. Holzhausen, G. Selvaggi, J. Zhou, L. Horn
Journal: Journal of Thoracic Oncology (2019)
EXTH-33. RECEPTOR PHARMACOLOGY OF ONC201: THE FIRST BITOPIC DRD2 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY
Authors: R Benjamin Free, Caroline Cuoco, Varun Prabhu, Blair Willette, Marilyn Day, Lakshmi Anantharaman, Chidananda Sulli, Edgar Davidson, Sean Deacon, Joseph Rucker, Neil Charter, Benjamin Doranz, Wolfgang Oster, Martin Stogniew, J Robert Lane, David Sibley, Joshua Allen
Journal: Neuro-Oncology (2019)

Abstract ONC201 has exhibited durable tumor regressions in midline high grade glioma patients. G protein-coupled receptor (GPCR) dopamine receptor D2 (DRD2) is overexpressed in high grade gliomas, controls several oncogenic mechanisms, and its antagonism causes tumor cell apoptosis. Using bioinformatic and GPCR screens, we previously demonstrated selective DRD2/3 antagonism by ONC201 at therapeutic concentrations that translates into a wide therapeutic window, unlike antipsychotics that also target other dopamine receptors and GPCRs (Prabhu et al. CCR 2019 and Madhukar et al. Nat Comm in press). Here, we identify hallmarks of non-competitive DRD2 antagonism by ONC201 in β-arrestin, cAMP and radioligand competition assays. ONC201 caused both a shift in the IC50 and repression of Emax in the dopamine-dose-response curves for DRD2. Schild analysis and fitting these data to an operational model of allostery were consistent with non-competitive antagonism. Alanine scanning mutagenesis of DRD2 identified 6 orthosteric and allosteric residues that are critical for ONC201-mediated antagonism. The residues identified were predominantly conserved in DRD2/3 and were not relevant for antagonism by antipsychotics further explaining the unique selectivity of ONC201. Molecular docking revealed orthosteric interactions at TM-II and an extended binding pocket into an allosteric site. Other critical residues were clustered at an allosteric area at the interface of TM-IV and –V that has been shown to mediate the DRD2 homodimer interface. Point mutations at either site decreased the affinity of ONC201 in competition assays with radiolabeled methyl-spiperone, suggesting cooperativity between these topographically distinct sites. In summary, ONC201 causes a mixed non-competitive and competitive antagonism of DRD2 consistent with a bitopic mechanism of action that may explain its unique selectivity, safety, and anti-cancer activity in clinical trials as the first compound to target this receptor for clinical neuro-oncology. Non-competitive DRD2 antagonism may be critical for ONC201 anti-tumor efficacy in dopamine-rich microenvironments such as midline gliomas.
The public health crisis of underimmunisation: a global plan of action
Authors: Lawrence O Gostin, James G Hodge, Barry R Bloom, Ayman El-Mohandes, Jonathan Fielding, Peter Hotez, Ann Kurth, Heidi J Larson, Walter A Orenstein, Kenneth Rabin, Scott C Ratzan, Daniel Salmon
Journal: The Lancet Infectious Diseases (2019)
Platelet Phenotype Prediction from Whole Genome Sequencing in 621 Sickle Cell Disease Patients
Authors: Celina Montemayor Garcia, Julie K. Weisman, Xunde Wang, Divya Gandla, James Owen Long, Clifton L. Dalgard, Mehdi Pirooznia, Harvey Klein, Swee Lay Thein
Journal: Blood (2019)
Total Skin Electron Beam Therapy in Patients with Advanced Cutaneous T Cell Lymphoma Undergoing Allogeneic Stem Cell Transplantation: A Single Centre Experience
Authors: Viviana Beatrice Valli, Filippo Grillo Ruggieri, Giorgia Saporiti, Silvia Alberti Violetti, Concetta Schiavone, Federica Irene Grifoni, Maria Cecilia Goldaniga, Francesca Casarin, Valeria Ferla, Luca Baldini, Emilio Berti, Francesco Onida
Journal: Blood (2019)
Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial
Authors: Féline P B Kroon, Marion C Kortekaas, Annelies Boonen, Stefan Böhringer, Monique Reijnierse, Frits R Rosendaal, Naghmeh Riyazi, Mirian Starmans, Franktien Turkstra, Jende van Zeben, Cornelia F Allaart, Margreet Kloppenburg
Journal: The Lancet (2019)
Easix Is Strongly Associated with Complement Activation and Overall Survival in Adult Allogeneic Hematopoietic Cell Transplantation Recipients
Authors: Eleni Gavriilaki, Ioanna Sakellari, Thomas Chatziconstantinou, Despina Mallouri, Ioannis Batsis, Anna Vardi, Zoi Bousiou, Evdoxia Koravou, Marianna Masmanidou, Tasoula Touloumenidou, Lila Papalexandri, Anastasia Athanasiadou, Evangelia Yannaki, Achilles Anagnostopoulos
Journal: Blood (2019)
Survival Analysis According to Minimal Residual Disease By Flow Cytometry in Acute Myeloid Leukemia after First Induction
Authors: Claudia Nunez-Torron, Juan Marquet Palomanes, Fernando Martín Moro, Adolfo Saez-Martin, Alejandro Luna, Irene Garcia-Garcia, Berta Mercedes Michael Fernández, Jesus Villarrubia, Miguel Piris-Villaespesa, Ernesto Roldan Santiago, Eulalia Rodríguez Martín, Gemma Moreno, Valentín García Gutiérrez, Javier Lopez Jimenez, Pilar Herrera Puente
Journal: Blood (2019)
Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion
Authors: S.S. Bielack, M.C. Cox, M. Nathrath, K. Apel, C. Blattmann, T. Holl, R. Jenewein, U. Klenk, P. Klothaki, P. Müller-Abt, S. Ortega-Lawerenz, M. Reynolds, M. Scheer, K. Simon-Klingenstein, S. Stegmaier, R. Tupper, C. Vokuhl, T. von Kalle
Journal: Annals of Oncology (2019)

The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib.A male infant born with a large congenital IFS of the tongue had the tumour surgically resected at age 4 days. Within 2 months, he developed extensive lymph node recurrence that progressed during two cycles of vincristine-doxorubicin-cyclophosphamide chemotherapy. At screening, a large right cervical mass was clinically visible. Magnetic resonance imaging (MRI) revealed bilateral cervical and axillary lymph node involvement as well as infiltration of the floor of the mouth. The largest lesion measured 5.5×4.5×4.4 cm (ca. 55 cm3). The patient started outpatient oral larotrectinib at 20 mg/kg twice daily at age 3.5 months.After 4 days on treatment, the parents noted that the index tumour was visibly smaller and softer. The rapid tumour regression continued over the following weeks. On day 56 of treatment, the first scheduled control MRI showed the target lesion had shrunk to 1.2×1.2×0.8 cm (ca. 0.6 cm3), corresponding to a complete response according to the Response Evaluation Criteria In Solid Tumors version 1.1. This response was maintained over subsequent follow-up visits, and on day 112 at the second control MRI the target lymph node was completely normal. At last follow-up, the disease remained in complete remission after 16 months on larotrectinib, with negligible toxicity and no safety concerns.Selective TRK inhibition by larotrectinib offers a novel, highly specific and highly effective therapeutic option for IFS carrying the characteristic ETV6-NTRK3 gene fusion. Its use should be considered when surgery is not feasible. (NCT02637687).
Impact of Graft-Versus-Host Disease and Graft-Versus-Leukemia Effect Based on Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Authors: Yu Akahoshi, Aiko Igarashi, Takahiro Fukuda, Naoyuki Uchida, Masatsugu Tanaka, Yukiyasu Ozawa, Yoshinobu Kanda, Makoto Onizuka, Tatsuo Ichinohe, Junji Tanaka, Yoshiko Atsuta, Shinichi Kako
Journal: Blood (2019)
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease
Authors: Eduardo Huarte, Melissa Parker, Ashish Juvekar, Julian Oliver, Wenqing Yao, Paul Smith
Journal: Blood (2019)
Efficient Ex Vivo Expansion of Highly Purified Human Umbilical Cord Blood-Derived Very Small CD34+lin-CD45- Stem Cells into Functional Endothelial Cells in Vitro in Chemically Identified, Feeder Layer-Free Medium Supplemented with Nicotinamide
Authors: Alison Domingues, Kamila Bujko, Magdalena Kucia, Janina Ratajczak, Mariusz Z Ratajczak
Journal: Blood (2019)
The SQSTM1-NUP214 Fusion Protein Cooperates with Crm1 to Activate Hoxa Genes and Drives Leukemogenesis in Mice
Authors: Waitman K. Aumann, Sei-Gyung K. Sze, Veerain Gupta, Katelyn Ripple, Sarah Port, Ralph Kehlenbach, Daniel S. Wechsler, Catherine P. Lavau
Journal: Blood (2019)
The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy
Authors: Abby Statler, Brian P. Hobbs, Tomas Radivoyevitch, Caitlin Siebenaller, Sudipto Mukherjee, Anjali S. Advani, Aaron T. Gerds, Aziz Nazha, Bhumika J. Patel, Hetty E. Carraway, Mikkael A. Sekeres
Journal: Blood (2019)
The Genome-Wide Impact of Trisomy 21 on DNA Methylation and Its Implications for Hematologic Malignancies
Authors: Joseph L. Wiemels, Ivo S Muskens, Shaobo Li, Priyatama Pandey, Ritu Roy, Helen M Hansen, Kimberly D Siegmund, Beth A Mueller, Xiaomei Ma, Catherine Metayer, Adam J de Smith
Journal: Blood (2019)
NCMP-06. THE INCIDENCE OF POST-IRRADIATION CAVERNOUS ANGIOMA AND CYSTIC MALACIA AFTER HIGH DOSE CRANIAL IRRADIATION IN PEDIATRIC AND ADULT MALIGNANT BRAIN TUMORS
Authors: Hiroki Taniguchi, Fumiyuki Yamasaki, Motoki Takano, Ushio Yonezawa, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2019)

Abstract PURPOSE The purpose of this study is to investigate the incidence of cavernous angioma (CVA) and cystic malacia in long-term survivors of pediatric and adult malignant brain tumors treated by cranial irradiation. MATERIALS AND METHODS 36 pediatric (age &lt; 18, M:F=24:12, mainly consisted of embryonal tumors) and 43 adults (age ≥18,M:F=27:16, mainly consisted of gliomas) patients with malignant tumors receiving high dose cranial irradiation and at least three years disease free period were included in this study. Follow-up of adult patients ranged from 3.2–19.4 years (median 7.6 years), the local irradiation dose from 50 to 60Gy. Follow-up of pediatric patients ranged from 3.8–18.4 years (median 9.0 years), the local irradiation dose from 49.6 to 60.4Gy. All patients underwent follow-up magnetic resonance imaging studies at least once a year, and the diagnosis of post-treatment CVA and cystic malacia was based solely on MRI findings. RESULTS At the timing of preparing this abstract, 16 adult patients developed CVAs during the median course of 13 years, while 24 pediatric patients developed CVAs during the median course of 5.8 years, and the difference was significant (P=0.0298, log-rank test). While, there was no statistical difference between adult and pediatric patients for the development of Zabramski type 1 &amp; 2 CVAs, or of cystic malacia (P=0.6254 and P=0.4652, respectively). CONCLUSION We attribute the high rate of post-RT CVAs in our long-term follow-up study of adult patients to the delivery of cranial irradiation for glioma patients. Our data imply the importance of long term follow-up not only for pediatric patients but also for adult patients after high dose cranial irradiation.
Complete Remission after the First Cycle of Induction Chemotherapy Determines the Clinical Efficacy of Relapse-Preventive Immunotherapy in Acute Myeloid Leukemia
Authors: Malin S Nilsson, Alexander Hallner, Mats Brune, Staffan Nilsson, Fredrik B Thorén, Anna Martner, Kristoffer Hellstrand
Journal: Blood (2019)
Coordination of Genetic Care: More Important and Complicated Than it Seems
Authors: Suzanne M. Mahon
Journal: Journal of the National Comprehensive Cancer Network (2019)

Families with hereditary risk for developing malignancy benefit from organized, coordinated care by a genetics professional. This report presents a case illustrating the potential errors that can occur when genetic care is fragmented and not coordinated, including ordering too much or not enough genetic testing, failing to communicate with the family who is at potential genetic risk, failing to communicate what the results of testing mean, and failing to recommend appropriate care, which may lead to psychosocial distress and late-detected cancers. This case highlights the complexities of genetic care and why management by a genetics professional results in more fiscally responsible care, appropriate genetic testing, and comprehensive care for all family members at risk.
Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib
Authors: Jennifer O'Sullivan, Jason A Taylor, Aaron T. Gerds, Sarah A Buckley, Claire N Harrison, Stephen T. Oh, Kieran Howard, Helene Marie-Pierre Dreau, Angela Hamblin, Adam J. Mead
Journal: Blood (2019)
Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome
Authors: Juan L Coelho-Silva, Douglas R. A. Silveira, Diego A Pereira-Martins, César Alexander Ortiz Rojas, Antonio R. Lucena-Araujo, Eduardo M Rego, João Agostinho Machado-Neto, Israel Bendit, Vanderson Rocha, Fabiola Traina
Journal: Blood (2019)
Carcinoma in situ
Authors: N. Bundred, J. M. Dixon
Journal: BMJ (2013)

copyrighted material, used by arrangement with john wiley & sons limited. for personal use only, must not be reproduced or shared with third parties. anyone wishing to reproduce this content in whole or in part, in print or in electronic format, should contact digitalrightsuk@wiley.com

browse the abc series at www.wiley.com

### Overview

Two main types of non-invasive (in situ) cancer can be recognised from the histological pattern of disease and cell type (Table 1). Ductal carcinoma in situ is the most common form of non-invasive carcinoma, making up 3–4% of symptomatic and 20–25% of screen-detected cancers. It has increased in frequency because of the widespread use of screening mammography (Figure 1). The increase is across all age groups, with a 12% annual increase in the 30–39-year age group and an 18.1% annual increase in women over the age of 50. Ductal carcinoma in situ is characterised by distortion, distention and complete involvement by a similar and neoplastic population of cells of adjacent ducts and lobular units (Figure 2). By contrast, lobular carcinoma in situ, now known as lobular intraepithelial neoplasia (LIN), which incorporates what was previously known as lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH), is rare (<1% of screen-detected cancers) and presents as relatively uniform expansion of the whole lobule by regular cells …
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
Authors: John E. Godwin, Carmen Ballesteros-Merino, Nikhil Lonberg, Shawn Jensen, Tarsem Moudgil, Carlo B Bifulco, Jon Wigginton, John Muth, Jan K Davidson-Moncada, Bernard Fox
Journal: Blood (2019)
Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)
Authors: Nathan Radakovich, Mikkael A. Sekeres, Cameron Beau Hilton, Sudipto Mukherjee, Jacob Shreve, Yazan Rouphail, Rachel Shirley, Vera Adema, Hassan Awada, Anjali S. Advani, Cassandra M Kerr, Yasunobu Nagata, Yihong Guan, Teodora Kuzmanovic, Metis Hasipek, Babal K. Jha, Jaroslaw P. Maciejewski, Aziz Nazha
Journal: Blood (2019)
The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement
Authors: Shonali Midha, Julio C. Chavez, Hayder Saeed, Celeste Bello, Farhad Khimani, Silvia Tse Bunting, Bijal Shah
Journal: Blood (2019)
A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function
Authors: Julio C. Chavez, Ariel F Grajales-Cruz, Virginia Olivia Volpe, Elyce P. Turba, Lisa Nodzon, Eva Sahakian, Nicole Rozario, Javier Pinilla Ibarz
Journal: Blood (2019)
Droplet Digital PCR Phasing (DROP-PHASE): A Novel Method for Straightforward Detection of BCR-ABL1 Compound Mutations in Tyrosine Kinase Inhibitors Resistant Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)
Authors: Pascal Vannuffel, Luana Bavaro, Friedel Nollet, Asena Aynaci, Margherita Martelli, Helena Devos, Céline De Rop, Simona Soverini
Journal: Blood (2019)
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloidosis
Authors: Larysa Sanchez, Heather J Landau, Cara A. Rosenbaum, Alex Abrahams, Cindy Chin, Brielle Liotta, Natalie Agudo, Sheetal Ramnath, Elizabeth Hoover, Hafsa Rahman, Umut Ozbek, Oscar B Lahoud, Hani Hassoun, Keren Osman
Journal: Blood (2019)